Overview

Epoprostenol in Pulmonary Embolism

Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
You are admitted to hospital because of pulmonary embolism. You are treated with anticoagulants. The investigators know that, despite this treatment, pulmonary embolism can be a threat especially if heart function is compromized. The investigators investigate a well known study drug (epoprostenol) on top of regular treatment with anticoagulants, to see if heart function can be optimized
Phase:
Phase 4
Details
Lead Sponsor:
Free University Medical Center
Treatments:
Epoprostenol
Tezosentan